A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that treatment with dupilumab significantly restores skin barrier function and reduces inflammation in children ages 6 to 11 with moderate-to-severe atopic dermatitis (eczema). Using advanced, noninvasive techniques, researchers found improvements not only in visible eczema lesions but also in clinically unaffected skin, highlighting the systemic nature of the disease.
This article was originally published on MedicalXpress.com
